Q1 26 EPS
$0.80
Q1 26 Revenue
$5.20B
BEAT +0.60%
Est. $5.17B
vs S&P Since Q1 26
-6.9%
TRAILING MARKET
BSX -5.6% vs S&P +1.3%
Market Reaction
Did BSX Beat Earnings? Q1 2026 Results
Boston Scientific posted a convincing beat to open fiscal 2026, with first-quarter revenue of $5.20 billion growing 11.6% year-over-year and adjusted EPS of $0.80 edging past the $0.79 consensus by 1.61%, extending the company's streak of consensus E… Read more Boston Scientific posted a convincing beat to open fiscal 2026, with first-quarter revenue of $5.20 billion growing 11.6% year-over-year and adjusted EPS of $0.80 edging past the $0.79 consensus by 1.61%, extending the company's streak of consensus EPS beats to four consecutive quarters. The primary engine behind the quarter was a surging Cardiovascular segment, which generated $3.50 billion in sales at 13.5% reported growth, fueled by strong adoption of devices like the WATCHMAN FLX and FARAPULSE pulsed field ablation system, the latter showing sustained superiority over thermal ablation at four years in long-term trial data. Organic growth of 9.4% exceeded even Boston Scientific's own guidance range of 8.5 to 10.0%, underscoring the breadth of demand across its portfolio. Looking ahead, management guided full-year 2026 adjusted EPS of $3.34 to $3.41 on reported revenue growth of 7.0 to 8.5%, with the sequential deceleration in Q2 guidance reflecting cautious assumptions around tariff-related and macroeconomic uncertainty, even as analysts broadly maintain positive ratings on the stock despite recent share price pressure.
Key Takeaways
- • Cardiovascular segment growth of 13.5% reported driven by strong global adoption
- • Neuromodulation growth of 17.4% reported, strongest sub-segment growth
- • Organic growth of 9.4% exceeded high end of company guidance range
- • Asia Pacific operational growth of 12.0% and Latin America operational growth of 12.0%
- • Category leadership strategy across all business segments
BSX Forward Guidance & Outlook
For full year 2026, Boston Scientific estimates net sales growth of approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis, with adjusted EPS of $3.34 to $3.41. For Q2 2026, the company estimates net sales growth of approximately 5.5 to 7.5 percent on a reported basis and 5.0 to 7.0 percent on an organic basis, with adjusted EPS of $0.82 to $0.84.
BSX YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
BSX Revenue by Segment
With YoY comparisons, source: SEC Filings
BSX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter. We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems.”
— Mike Mahoney, Q1 2026 Earnings Press Release
BSX Earnings Trends
BSX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BSX EPS Trend
Earnings per share: estimate vs actual
BSX Revenue Trend
Quarterly revenue: estimate vs actual
BSX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.80 | — | $5.20B | +0.60% |
| Q4 25 BEAT FY | $0.78 | $0.80 | +2.56% | $5.29B | +0.04% |
| FY Full Year | $3.04 | $3.06 | +0.80% | $20.07B | +0.01% |
| Q3 25 BEAT | $0.71 | $0.75 | +5.09% | $5.07B | +1.83% |
| Q2 25 BEAT | $0.73 | $0.75 | +3.42% | $5.06B | +3.39% |
| Q1 25 BEAT | $0.67 | $0.75 | +11.52% | $4.66B | +1.98% |